# Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

> **NCT01606384** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 100 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01606384
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2012-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606384, "Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01606384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*